David Malek Purchases 4,166 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Malek acquired 4,166 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $74,988.00. Following the completion of the acquisition, the director directly owned 533,845 shares of the company’s stock, valued at $9,609,210. This trade represents a 0.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Braveheart Bio Trading Up 0.7%

Braveheart Bio stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a fifty-two week low of $28.47 and a fifty-two week high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.